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Abstract
Objective Blood lead (B–Pb), one of the most used tox-
icological biomarker all kind, has serious limitations. Thus,
the objective is to evaluate whether plasma lead (P–Pb) is
more adequate.
Methods A long-term follow-up study of ﬁve cases of
lead poisoning. P–Pb was analysed by inductively coupled
plasma mass spectrometry. Kinetics after end of exposure
was modelled.
Results P–Pb at severe poisoning was about 20 lg/L;
haematological effects at about 5 lg/L. Biological half-
time of P–Pb was about 1 month; B–Pb decay was much
slower.
Conclusion P–Pb is a valuable biomarker of exposure to
and risk, particularly at high exposure.
Keywords Human   Urine   Pb   Kinetics   Modelling  
Risk
Introduction
The lead (Pb) concentration in whole blood (B–Pb) is
probably—next to ethanol in blood—the most widely used
biomarker for assessment of toxic exposure and risk.
However, it has clear limitations, in particular because
there is saturation with increasing exposure, in particular at
B-Pbs[700 lg/L (Bergdahl et al. 1999), and because Pb
induces anaemia (Skerfving and Bergdahl 2007), which
will make the use of B–Pb problematic, because Pb is
mainly present in erythrocytes, the volume of which will
decrease. Pb in plasma (P–Pb) or serum is an attractive
alternative, which would avoid these problems (Schu ¨tz
et al. 1996; Costa de Almeida et al. 2010; Montenegro et al.
2006; Hirata et al. 1995). The concentrations are very low,
but the developments in analytical technique now allow
adequate determination. However, P–Pb has up to now
been used only occasionally.
There are indications that the toxicokinetics of Pb are
affected by genetic polymorphism in the enzyme d-amino-
levulinic acid dehydratase (ALAD), which is the main
binding site for Pb in erythrocytes, and inhibition of which
is at least partly responsible for the anaemic effect of Pb
(Skerfving and Bergdahl 2007).
In spite of centuries of preventive attempts, Pb is still a
major health problem. It induces clinical poisoning in
occupational settings, but sometimes also by other expo-
sures (Skerfving and Bergdahl 2007).
The aim of this study was to scrutinise the usability of
P–Pb as a biomarker in cases of clinical Pb poisoning.
Subjects and methods
Cases
We evaluated data from ﬁve cases of clinical Pb poisoning,
four non-occupational and one occupational (Table 1).
They had been exposed to Pb for 1 month–12 years. The
intakes of Pb were estimated by self-reported consumption
of tablets or drink, and the measured contents of Pb in
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DOI 10.1007/s00420-011-0673-0those media. Four had anaemia. They were followed for
21–316 months. In all subjects, the symptoms and signs
disappeared during the initial part of the follow-up.
Blood and urine for Pb and haemoglobin (B-Hb)
determinations were sampled daily during the ﬁrst week(s),
later on weekly, monthly or more rarely.
All cases gave written informed consent for the use of
their data for this study. Because of uncertainty in the
diagnosis, and whether the exposure had ceased, frequent
sampling was made initially.
Analyses
Lead
Cubital venous blood was collected in evacuated metal-free
heparinised tubes. To obtain plasma, the tubes were cen-
trifuged at 2,000g for 10 min. Samples with haemolysis at
inspection were deleted. In connection with most blood
sampling occasions, spot urine samples were collected in
10 mL polypropylene tubes the same day or the day before.
All samples, but those from case 5, were analysed by
inductively coupled plasma–mass spectrometry (ICP-MS;
Barany et al. 2002); for the samples from case 5, electro
thermal atomic absorption spectrometry (ETA-AAS) was
used. All samples were prepared in duplicate.
Quality control was strict, especially at method changes
(ETA-AAS vs. ICP-MS, r = 0.98, n = 29; Stro ¨mberg
et al. 2008). The analytical accuracy was checked against
reference material, (Seronorm, SERO AS, Billingstad,
Norway) with the recommended values for lead in blood,
plasma and urine being 393, 0.9 and 40 lg/L, respectively.
Our results for the lead determination in the reference
samples during the follow-up time were 98, 106 and 101%
for blood, plasma and urine, respectively. Our laboratory is
accredited for lead analysis in blood according to the
Swedish Board for Accreditation and Conformity Assess-
ment (SWEDAC), and during the period, we also produced
good results in the UK National External Quality Assess-
ment Service (Birmingham, UK); our mean accuracy was
96% with coefﬁcient of variation\5%.
Other
Blood haemoglobin (B-Hb) was analysed by a standard
clinical method. Creatinine (crea) was analysed in urine
samples by a modiﬁed kinetic Jaffe ´ method (Roche Diag-
nostics, Mannheim, Germany). Both B-Hb and crea were
analysed by an accredited clinical laboratory with scrupu-
lous quality control. Detection limit for crea was 0.1 mmol/L
and total imprecision 1.6%. For B-Hb measurements, the
imprecision within the working range of 1–250 g/L was
B1.0%.
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123Toxicokinetic modelling
Non-linear regression analysis was performed with SPSS
version 15.0, according to Eq. (1). The ﬁrst exponential
term describes the fast elimination phase, the second one,
the slow elimination of Pb.
CPbðtÞ¼C1   eð R1 tÞ þ C2   eð 0:000146 tÞ ð1Þ
CPb(t), lead concentration at a given time (lg/L), t, time
(days), C1, constant (concentration of the fast phase at
t = 0), C2, constant (concentration of slow phase at t = 0),
R1, elimination constant of phase 1 (days
-1).
The follow-up time was not sufﬁcient to calculate the
half-time in the slow phase. Nilsson et al. (1991) found it to
be 13 years in a long-term study of Pb workers. Therefore,
that value was used. The sum of C1 and C2 describes the
modelled Pb content at the end of exposure (t = 0). The
half-time of Pb in the fast phase has been calculated
according to Eq. (2).
T1= 2 ¼ ln2=R1 ð2Þ
For three cases, there were sufﬁcient data to describe the
relationship between B–Hb and P–Pb after end of expo-
sure. Inspection of the curves (Fig. 4) indicated that one
component did not give a satisfactory ﬁt. Regression lines
were calculated on the left and right sides of the division
line (x = 5 lg P–Pb/L), and statistical signiﬁcance of the
difference between the pairs of slopes was examined. After
that the threshold between the two components was cal-
culated as the crossing point of the two lines.
Genotyping
DNA was isolated from whole blood by minicolumn puri-
ﬁcation (E.Z.N.A DNA extraction kit, Omega Bio-Tek,
Norcross, GA, USA) and diluted to a concentration of
5 ng/lL. The ALAD G379C polymorphism (Asn59Lys,
rs1800435)wasgenotypedbyTaqmanallelicdiscrimination
assay (ABI 7000 instrument, Applied Biosystems, Foster
City, CA, USA), using the following primers and probes for
ALAD: primers forward: 50-TGC CTT CCT TCA ACC CCT
CTA-30 and reverse: 50-CCA AGG GCC TCA GCA TCT
C-30;MGB-probes:ALAD-G:50-Fam-TGTGAAGCGGCT
GG-30 and ALAD-C: 50-Vic-TGT GAA CCG GCT GG-30.
ThetotalvolumeofthePCRwas25 lL.Primerswereadded
to a ﬁnal concentration of 0.05 lM, probes to 0.9 lMi na n
80% concentrated TaqMan Universal PCR Master Mix
(Applied Biosystems, Foster City, CA, USA). The PCR
samples were incubated at 50C for 2 min and at 95C for
10 min. The samples underwent 40 cycles of 15 s at 95C
and 1 min at 60C. Controls for each genotype as well as
blanks were included in each run. Samples were analysed in
duplicate and concordance rate was 100%.
Results
The median P–Pb at ﬁrst sampling (median 5, range
1–74 days after end of exposure) was 17 (range 2–42) lg/L
(Fig. 1a). The modelled median value for P–Pb (C1 ? C2)
was 23 (range 3–38) lg/L at time t = 0. In Cases 1–4, the
median of C2 was 0.65 (range 0.6–0.8) lg/L, in Case 5
1.6 lg/L.
In the two-compartment model, the median biological
T1/2 of the fast P–Pb phase was 27 (23–69) days (Table 2).
The median B–Pb at ﬁrst sampling was 790 (520–1,600)
lg/L (Fig. 1b). The modelled median value for B–Pb
(C1 ? C2) was 840 (range 790–1,300) lg/L at time t = 0.
In Cases 1–4, the median of C2 was 155 (range 83–230) lg/L
and in Case 5, it was 290 lg/L.
Median T1/2 for the fast B–Pb component was 77
(58–120) days (Table 2).
The relationship between B–Pb and P–Pb was approxi-
mately linear at low levels (ratio about 100); at P-Pbs
above about 5 lg/L, the B–Pb levelled off (Fig. 2). In
Cases 1 and 2, the ratio at the highest P-Pbs was about 40,
in Case 5, it was about 60.
There seemed to be a rectilinear relationship between
U–Pb and P–Pb; the former expressed as lg/g crea was
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Fig. 1 Lead elimination from plasma (P–Pb; a) and whole blood
(B–Pb; b) during the ﬁrst 800 days after end of exposure in ﬁve cases
of poisoning
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12322 times higher than the latter (R
2 linear = 0.5;
p\0.001), expressed as lg/L (Fig. 3).
The median B-Hb rose after end of exposure, from a
median of 108 (range 92–139) g/L (Table 1) at the time of
the ﬁrst blood sampling to 138 (122–155) g/L at end of
follow-up (not in table). In all patients, B-Hb values
recovered to a stable level for each individual within a
median time of 176 (range 145–230) days.
In three cases, there was sufﬁcient information for a
meaningful study of the relationship between B–Hb and
P–Pb (Fig. 4). The association seemed to have two com-
ponents, an initial fast increase at relatively low P-Pbs, and
a slower one at high ones (all Ps for pairs of regression
lines B 0.01). The threshold P–Pb between the two com-
ponents was calculated at 4.3, 6.6 and 5.0 lg/L, in Cases 1,
2 and 5, respectively.
Case 5, who was the only heterozygote for ALAD
G379C (earlier denoted as ALAD 1–2; Table 1), had the
longest T1/2 for B–Pb, as compared to the others, who were
homozygotes for the more common G-allele, while he did
not differ from the others in P–Pb kinetics (Table 2). Also,
he had higher initial both B–Pb and P–Pb (Fig. 1), and a
higher B–Pb/P–Pb ratio (Fig. 2).
Discussion
The most important ﬁnding was that P–Pb at poisoning
was about 20 lg/L. Biological half-time of P–Pb was about
Table 2 Two-compartment modelling of lead in plasma and whole blood after end of exposure in ﬁve cases of lead poisoning
Case Plasma Whole blood
First component Second component First component Second component
C1 (CI) (lg/L) T1/2 (CI) (d) C2 (CI) (lg/L) C1 (CI) (lg/L) T1/2 (CI) (d) C2 (CI) (lg/L)
1 30 (25, 35) 23 (18, 30) 0.6 (0.0, 1.8) 770 (720, 810) 77 (63, 87) 83 (41, 120)
2 22 (19, 25) 27 (22, 35) 0.8 (0.0, 1.6) 700 (660, 750) 87 (77, 120) 140 (120, 190)
3 37 (0, 91) 23 (15, 43) 0.7 (0.5, 0.8) 660 (640, 1,100) 58 (46, 77) 170 (170, 190)
4 3 (2, 4) 46 (24, 350) 0.6 (0.3, 1.1) 560 (500, 620) 63 (46, 87) 230 (190, 270)
5 30 (23, 37) 69 (46, 170) 1.6 (0.0, 7.2) 1,100 (1,000, 1,100) 120 (120, 140) 290 (250, 330)
C1 and C2 are concentrations at t = 0 for the fast and slow components. T1/2 half-time. CI 95% conﬁdence interval
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1231 month; decay in B–Pb was much slower. P–Pb displayed
a non-linear relationship with B–Pb, but rectilinear with
U–Pb.
The number of cases was small; in particular, we had
only three cases with valid information on long-term B-Hb,
which must be taken into consideration when drawing
conclusions.
Since Pb content in red blood cells is much higher than
in plasma, there is a risk that even a rather limited haem-
olysis, which may occur because of the haemolytic ten-
dency at high Pb exposure, may contaminate the P–Pb. We
eliminated the few plasma samples with haemolysis. A
very slight red colour occurs before there is a serious
problem of Pb carryover.
The present determination of P–Pb by ICP-MS was
accurate. However, there is still uncertainty, which is
reﬂected in the large conﬁdence intervals in the estimates
of kinetic parameters for P–Pb, which is wider than for
B–Pb. In particular, Case 5 was studied before develop-
ment of that method. Hence, ETA-AAS was used for P–Pb
analyses, which was less sensitive. This is also obvious
from the much greater variation of his data points in the
elimination and B–Pb/P–Pb, U–Pb/P–Pb and B–Hb/P–Pb
curves. This also explains why his ﬁrst and third mea-
surements are higher than the modelled C1 ? C2. How-
ever, it is most unlikely that the analytical method explains
his higher P–Pbs in general, which are more likely due to
his greater skeletal Pb pool.
The elimination of Pb from both plasma and whole
blood displayed at least two phases. The fast one reﬂects
the soft tissues, the slow one the skeleton (Schu ¨tz et al.
1987; Nilsson et al. 1991). In spite of the long follow-up
times, they did still not allow accurate estimates of the slow
phase. Thus, we choose to use the better value obtained in
our earlier study. The present P–Pbs are much higher than
those in Swedes with no particular exposure (0.1–0.3 lg/L
(Schu ¨tz et al. 1996; Bergdahl et al. 1999), and remained so
long after end of exposure. Therefore, we did not subtract a
level in Swedish subjects without excessive exposure.
The method for determination of P–Pb with ICP-MS has
beenfurtherdeveloped.Hence,atourlaboratory,thelimitof
detectionisnow0.02 lg/Landtheprecision6%.Hence,itis
possibletouseP–Pbasabiomarkerinenvironmentalhealth.
The number of cases is small, in particular we had only
three cases with valid information on long-term B-Hb,
which must be taken into consideration when drawing
conclusions. In addition, the time of exposure and the total
amount of Pb absorbed varied between the individuals; in
particular, Case 5 differed. Hence, the body burden (mainly
the skeletal content) of Pb differed, which will affect the
elimination pattern after end of exposure (Nilsson et al.
1991). This was accounted for by the use of a two-
component elimination model on an individual basis.
The relationship between the initial levels of the two
components will vary depending upon the bone pool versus
recent exposure. The pattern of P–Pb ﬁts better with
exposure data than B–Pb, which may be because it better
reﬂects uptake and body burden, especially at these high
uptakes. Only after careful comparison of the patterns did
we merge the information into combined conclusions.
The T1/2 for P–Pb of about 1 month is much longer
than that reported after intravenous injection of Pb salt
(Campbell et al. 1984).
The present T1/2s for B–Pb are longer than previously
reported (Schu ¨tz and Skerfving 1976; Rabinowitz et al.
1976; Schu ¨tz et al. 1987). This is certainly because the
present cases had B-Pbs much higher than in the earlier
studies. Thus, our subjects initially had anaemia, with an
attenuation of the rate of B–Pb decline when the effect on
the blood cell formation and survival decreases as the body
burden decays. Further – and more important – the curvi-
linear relationship between B–Pb and P–Pb, at the initial
decrease of the body burden, will not be reﬂected in a
simultaneous decay of B–Pb. Hence, our T1/2s of B-Pbs are
fully compatible with both the earlier reports on B–Pb and
our T1/2s for P–Pb. Also, the non-linear B–Pb/P–Pb rela-
tionship means that the B–Pb/P–Pb ratio will differ
between individuals and over time.
In spite of the time to diagnosis being long in some of
the cases, the modelling resulted in estimates of both the
B–Pb and the P–Pb content at t = 0, which marked the
actual end of exposure.
Poisoning with gastrointestinal, neurological and hae-
matological symptoms and signs occurred at P–Pbs of
about 20 lg/L as indicated by extrapolation of the P–Pb
curves. In one of the cases (no. 4), the P–Pb at diagnosis
was much lower. However, we are less certain of the rel-
evance, since the symptoms and signs were less convincing
for intoxication.
The present data clearly show the well-known anaemic
effect of Pb exposure (Bergdahl et al. 2006). Previous
authors have described the relationship between exposure
and B-Hb by use of B–Pb as a biomarker (Gennart et al.
1992). However, this may lead to spurious results, because
the effect causes a decrease of the assumed indicator of
exposure/risk, caused by the anaemia-induced decrease of
binding possibilities for Pb in blood, and the saturation of
binding sites. Our data clearly show the usefulness of P–Pb
as an indicator of the risk of haematological effects. The
shape of the B-Hb/P–Pb seemed to have at least two
components. This is probably because, as said above, Pb
has several different modes of action: inhibition of haem
synthesis, inhibition of nucleotide synthesis and haemoly-
sis. The present data does not allow allocation of these
mechanisms to the B-Hb/P–Pb curve, but it is obvious that
there is a dramatic effect at a P–Pb of about 5 lg/L.
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123Interestingly, Case 5, who was the only heterozygote for
ALAD G379C, had the longest T1/2 for B–Pb, as compared
to the others, who were homozygote for the C-allele, while
he did not differ from the others in P–Pb kinetics. Also, he
had a higher B–Pb/P–Pb ratio and higher initial B–Pb,
which is in accordance with earlier ﬁndings (Bergdahl et al.
1997; Fleming et al. 1998; Schwartz et al. 2000;M o n t e n e g r o
etal.2006).However,thehighB–Pbobservedmaybeduetoa
higher exposure, compared to the other cases.
Conclusions
The present B-Pbs at onset of poisoning are high, well
above occupational and other biological exposure limits
(Skerfving and Bergdahl 2007). However, the present
results are still relevant for evaluation of cases of poison-
ing. It is then important to consider that B–Pb, despite
being one of the most used toxicological biomarkers all
kind, has serious limitations because of the saturation at
high exposure. Then, P–Pb is a more adequate biomarker
of Pb exposure and risk than B–Pb, which is in accordance
with a closer association between P–Pb and markers of
haem synthesis, as compared to B–Pb, especially at high
exposure (Hirata et al. 1995). P–Pb at severe poisoning was
about 20 lg/L. Biological half-time of P–Pb was about
1 month; whole blood decay was much slower. The ALAD
genotype seemed to modify the toxicokinetics (higher level
and slower elimination in whole blood), though only one of
our cases was a heterozygote.
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